

Table 1.

Trade associations criticizing the IP regime in India in their submission to USTR	Designate as a Priority Foreign Country in the Special 301 Report
U.S. Chamber of Commerce	Yes
Alliance for Fair Trade	Yes
Pharmaceutical Research and Manufacturers of America	Yes
National Association of Manufacturers	Yes
Biotechnology Industry Organization	Yes
National Foreign Trade Council	Yes
International Intellectual Property Alliance	No
Intellectual Property Owners Association	No

Source: Regulations.gov.

Table 2.

Company	Drug	Action Taken	Reason Provided by India's Patent Board (2013)
Bayer	Nexavar	Compulsory License	Public Interest
Novartis	Glivec	Patent Denied	Did not clearly demonstrate " enhanced efficacy "
GlaxoSmithKline	Tykerb	Patent Revoked	Incremental innovation over original compound
Allergan	Ganfort	Patent Revoked	Incremental innovation over the existing drug
Allergan	Combigan	Patent Revoked	Incremental innovation over the existing drug

Source: Intellectual Property Appellate Board, India.